Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Onconova therapeutics, inc. save search
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
Published: 2021-06-28 (Crawled : 12:00) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 1.12%
H: 3.46%
C: 2.63%
lung cancer phase 1 cancer trial phase 2 nivolumab
Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300
Published: 2021-05-21 (Crawled : 12:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -10.5%
H: 10.61%
C: -5.82%
phase 1 trial phase 3 phase 2
Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Published: 2021-04-22 (Crawled : 14:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 8.46%
H: 13.92%
C: 12.14%
phase 2 initiated cell carcinoma
Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China
Published: 2021-04-01 (Crawled : 12:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 4.11%
H: 0.96%
C: -8.76%
phase 1 china phase 3 phase 2 enroll
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.79%
H: 6.33%
C: 2.38%
treatment phase 3 phase 1 phase 2 nivolumab
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
Published: 2020-07-07 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: -1.07%
H: 4.7%
C: 2.69%
risk results leukemia research phase 3 phase 1 phase 2
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Published: 2020-09-21 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 24.3%
H: 9.9%
C: -9.03%
china biopharma trial phase 3 phase 1 phase 2
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.75 79.52% 1.5M
|
CZOO | $8.77 75.75% 11M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
CMAX | $4.12 28.35% 65K
|
Manufacturing
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.